MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

Search

Avidity Biosciences Inc

Cerrado

SectorSalud

31.04 1.04

Resumen

Variación precio

24h

Actual

Mínimo

30.3

Máximo

31.38

Métricas clave

By Trading Economics

Ingresos

-22M

-102M

Ventas

637K

3M

BPA

-0.8

Margen de beneficio

-3,439.522

Empleados

391

EBITDA

-23M

-120M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+119.94% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-214M

3.4B

Apertura anterior

30

Cierre anterior

31.04

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Avidity Biosciences Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 abr 2025, 09:30 UTC

Principales Noticias

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Comparación entre iguales

Cambio de precio

Avidity Biosciences Inc Esperado

Precio Objetivo

By TipRanks

119.94% repunte

Estimación a 12 meses

Media 67.83 USD  119.94%

Máximo 96 USD

Mínimo 48 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Avidity Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

12

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

25.8 / 30.93Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.